Veronique M. Braud

Dr. Veronique M. Braud

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1998 in Nature
Verified
Journal Article
Closed access
PDF file
VBVeronique M. Braud
Veronique M. Braud
DADavid S. J. Allan
David S. J. Allan
COChristopher A. O'Callaghan
Christopher A. O'Callaghan
KSKalle Söderström
Kalle Söderström
ADAnnalisa D'Andrea
Annalisa D'Andrea
AMAndrew J. McMichael
Andrew J. McMichael

11 February 2000 in Science
Verified
Journal Article
Closed access
PDF file
PTPeter Tomasec
Peter Tomasec
VBVeronique M. Braud
Veronique M. Braud
CRCarole Rickards
Carole Rickards
MPMartin B. Powell
Martin B. Powell
BMBrian McSharry
Brian McSharry
GWGavin W. G. Wilkinson
Gavin W. G. Wilkinson
The nonclassical major histocompatibility complex (MHC) class I molecule HLA-E inhibits natural killer (NK) cell–mediated lysis by interacting with CD94/NKG2A receptors. Surface expression of HLA-E depends on binding of conserved peptides derived from MHC class I molecules. The same peptide is present in the leader sequence of the human cytomegalovirus (HCMV) glycoprotein UL40 (gpUL40). It is shown that, independently of the transporter associated with antigen processing, gpUL40 can up-regulate expression of HLA-E, which protects targets from NK cell lysis. While classical MHC class I molecules are down-regulated, HLA-E is up-regulated by HCMV. Induction of HLA-E surface expression by gpUL40 may represent an escape route for HCMV.

9 July 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MSMitsunori Shiroishi
Mitsunori Shiroishi
KTKouhei Tsumoto
Kouhei Tsumoto
KAKimie Amano
Kimie Amano
YSYasuo Shirakihara
Yasuo Shirakihara
MCMarco Colonna
Marco Colonna
KMKatsumi Maenaka
Katsumi Maenaka
Ig-like transcript 4 (ILT4) (also known as leukocyte Ig-like receptor 2, CD85d, and LILRB2) is a cell surface receptor expressed mainly on myelomonocytic cells, whereas ILT2 (also known as leukocyte Ig-like receptor 1, CD85j, and LILRB1) is expressed on a wider range of immune cells including subsets of natural killer and T cells. Both ILTs contain immunoreceptor tyrosine-based inhibitory receptor motifs in their cytoplasmic tails that inhibit cellular responses by recruiting phosphatases such as SHP-1 (Src homology 2 domain containing tyrosine phosphatase 1). Although these ILTs have been shown to recognize a broad range of classical and nonclassical human MHC class I molecules (MHCIs), their precise binding properties remain controversial. We have used surface plasmon resonance to analyze the interaction of soluble forms of ILT4 and ILT2 with several MHCIs. Although the range of affinities measured was quite broad (Kd= 2–45 μM), some interesting differences were observed. ILT2 generally bound with a 2- to 3-fold higher affinity than ILT4 to the same MHCI. Furthermore, ILT2 and ILT4 bound to HLA-G with a 3- to 4-fold higher affinity than to classical MHCIs, suggesting that ILT/HLA-G recognition may play a dominant role in the regulation of natural killer, T, and myelomonocytic cell activation. Finally, we show that ILT2 and ILT4 effectively compete with CD8 for MHCI binding, raising the possibility that ILT2 modulates CD8+T cell activation by blocking the CD8 binding as well as by recruiting inhibitory molecules through its immunoreceptor tyrosine-based inhibitory receptor motif.

1 May 1997 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
VBVeronique M. Braud
Veronique M. Braud
EJE. Yvonne Jones
E. Yvonne Jones
AMAndrew McMichael
Andrew McMichael

1 June 2000 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
AKAshley King
Ashley King
DADavid S. J. Allan
David S. J. Allan
MBMark Bowen
Mark Bowen
SPSimon J. Powis
Simon J. Powis
SJSarah Joseph
Sarah Joseph
VBVeronique M. Braud
Veronique M. Braud
Non‐classical MHC class I molecule HLA‐E is the ligand for CD94 / NKG2 NK cell receptors. Surface expression of HLA‐E requires binding of specific HLA class I leader sequences. The uterine mucosa in early pregnancy (decidua) is infiltrated by large numbers of NK cells, which are closely associated with placental trophoblast cells. In this study we demonstrate that trophoblast cells express HLA‐E on their cell surface in addition to the previously reported expression of HLA‐G and HLA‐C. Furthermore, we show that the vast majority of decidual NK cells bind to HLA‐E tetrameric complexes and this binding is inhibited by mAb to CD94. Thus, recognition of fetal HLA‐E by decidual NK cells may play a key role in regulation of placentation. The functional consequences of decidual NK cell interaction were investigated in cytotoxicity assays using polyclonal decidual NK cells. The overall effect of CD94 / NKG2 interaction with HLA‐E is inhibition of cytotoxicity by decidual NK cells. However, since decidual NK cells are unable to kill trophoblast even in the presence of mAb to MHC class I molecules and NK cell receptors, HLA‐E interaction with CD94 / NKG2 receptors may regulate other functions besides cytolysis during implantation.

18 May 2004 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
PHPokrath Hansasuta
Pokrath Hansasuta
TDTao Dong
Tao Dong
HTHathairat Thananchai
Hathairat Thananchai
MWMichael Weekes
Michael Weekes
CWChristian Willberg
Christian Willberg
VBVeronique M. Braud
Veronique M. Braud
The recognition of MHC class I molecules by killer cell immunoglobulin‐like receptors (KIR) is central to the control of NK cell function and can also modulate the CTL activation threshold. Among KIR receptors, KIR3DL2 is thought to interact with HLA‐A3 and ‐A11, although direct evidence has been lacking. In this study, we show that HLA‐A3 and ‐A11 tetramers specifically bind to KIR3DL2*001 transfectants and that this recognition is peptide‐specific. Single amino acid substitutions in the nonamer peptide underline a critical role for residue 8 in recognition of KIR3DL2. However, the role of this interaction in vivo still remains to be established.